Arizona State Retirement System Acquires 200 Shares of CryoLife, Inc. (CRY)

Arizona State Retirement System raised its holdings in CryoLife, Inc. (NYSE:CRY) by 1.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,254 shares of the medical equipment provider’s stock after buying an additional 200 shares during the period. Arizona State Retirement System’s holdings in CryoLife were worth $284,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. lifted its stake in shares of CryoLife by 30.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 149,791 shares of the medical equipment provider’s stock valued at $2,989,000 after buying an additional 35,247 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of CryoLife in the second quarter valued at about $291,000. Essex Investment Management Co. LLC raised its holdings in shares of CryoLife by 21.9% in the second quarter. Essex Investment Management Co. LLC now owns 117,849 shares of the medical equipment provider’s stock valued at $2,351,000 after purchasing an additional 21,206 shares during the last quarter. Texas Permanent School Fund raised its holdings in shares of CryoLife by 1.7% in the second quarter. Texas Permanent School Fund now owns 19,913 shares of the medical equipment provider’s stock valued at $397,000 after purchasing an additional 333 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its holdings in shares of CryoLife by 3.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock valued at $127,000 after purchasing an additional 230 shares during the last quarter. 68.85% of the stock is currently owned by hedge funds and other institutional investors.

In other CryoLife news, CEO James P. Mackin sold 125,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the transaction, the chief executive officer now owns 398,399 shares in the company, valued at approximately $8,768,761.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the transaction, the vice president now owns 112,282 shares in the company, valued at approximately $2,245,640. The disclosure for this sale can be found here. In the last quarter, insiders sold 178,627 shares of company stock worth $3,915,765. 6.00% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Arizona State Retirement System Acquires 200 Shares of CryoLife, Inc. (CRY)” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/09/12/arizona-state-retirement-system-acquires-200-shares-of-cryolife-inc-cry.html.

Shares of CryoLife, Inc. (NYSE:CRY) opened at 22.40 on Tuesday. The stock has a 50 day moving average of $19.46 and a 200 day moving average of $18.19. CryoLife, Inc. has a one year low of $14.02 and a one year high of $22.85. The stock has a market cap of $749.19 million, a P/E ratio of 67.88 and a beta of 0.97.

CryoLife (NYSE:CRY) last announced its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. The company had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. CryoLife’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.13 EPS. On average, analysts forecast that CryoLife, Inc. will post $0.43 EPS for the current year.

Several brokerages have recently commented on CRY. BidaskClub downgraded shares of CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. CryoLife presently has a consensus rating of “Hold” and an average target price of $22.00.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply